Trial Profile
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Ilacirnon (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2011 Results have been presented at the 47th Annual Meeting of the European Association for the Study of Diabetes, according to a ChemoCentryx media release.
- 22 Jul 2011 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.